Ziopharm Oncology Soars High (NASDAQ:ZIOP)

On early Wednesday morning shares of Ziopharm Oncology moved up a whopping 37 percent after they announced the release of the promising data of their cancer drug Zymafos. The company said that the interim data shows that their cancer drug Zymafos has met the efficacy milestones and this could be good news for Ziopharm Oncology as they are able to see direct and positive effects on their share prices. The company also mentioned that they have currently stopped enrollment for the trial as their cancer drug have met the primary endpoint. The trial is evaluating Zymafos or better known as palifosfamide, as a treatment for patients with metastatic or unresectable soft-tissue sarcoma.

For the trial, Ziopharm Oncology has divided the sarcoma patients into two groups. The first group will receive doxorubicin for their treatments and the second group will receive doxorubicin and palifosfamide to evaluate the new cancer drug made by the developers. According to the company, around 58 patients are being evaluated for progression-free survival with 19 PFS events successfully documented. The interim data showed that the addition of palifosfamide does not add to the toxicity of single agent doxorubicin. The company has announced that they will provide the detailed data soon in the coming month and after that they will intend to seek US regulatory approval.